Status:
COMPLETED
Assessment of the Effect of Captopril Versus Combination of Captopril and Pentoxifylline on Reducing Proteinuria in Type 2 Diabetic Nephropathy
Lead Sponsor:
Shiraz University of Medical Sciences
Conditions:
Diabetic Nephropathy
Eligibility:
All Genders
30-70 years
Phase:
PHASE2
PHASE3
Brief Summary
Diabetic nephropathy is the most common cause of ESRD and has a great impact on mortality and morbidity of diabetic patients. Despite renoprotective effect of ACE inhibitors in diabetic patients they ...
Detailed Description
Diabetic nephropathy is the most common cause of ESRD and has a great impact on mortality and morbidity of diabetic patients. Despite renoprotective effect of ACE inhibitors in diabetic patients they ...
Eligibility Criteria
Inclusion
- Absence of kidney or urinary tract disease
- Absence of high blood pressure OR Controlled blood pressure (≤140/90) with medication other than ACE inhibitors and/or non dihydropyridine calcium channel blockers
- A well controlled blood sugar level (HbA1c≤7.5%)
- Adhering to the diet protocol for patients with renal disease
Exclusion
- NYHA functional class III, IV
- Valvular heart disease
- Unstable angina, myocardial infarction, cerebrovascular accidents
- Psychiatric disease
- Prior allograft kidney transplant
- Acute illness
- Infectious disease including urinary tract infection
- Leukocytosis or any febrile illness at enrollment
- Prior history or development of any form of malignancy
- History of alcohol or drug abuse or smoking
- Pregnancy
- Need for surgery during the study
- Allergy to derivatives of methyl xanthines
- Current Pentoxyphilline use
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00663949
Start Date
February 1 2006
End Date
January 1 2008
Last Update
April 22 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shiraz University of Medical Sciences ,Nemazee and Faghihi Hospital
Shiraz, Fars, Iran, 0098